Heterogenous uptake of 68Ga-DOTATATE and 18F-FDG in patients with initially diagnosed neuroendocrine tumors: Which patients are suitable for dual-tracer PET imaging?

#3940

Introduction: PET scans using FDG and DOTATATE have both been used to study neuroendocrine tumors (NETs).

Aim(s): We aimed to assess the uptake heterogeneity in NET patients at initial diagnosis with dual-tracer PET imaging and the staging and prognostic value to explore the indication of the use of dual-tracer PET.

Materials and methods: Fifty-one patients with pathologically confirmed NET who underwent baseline 18F-FDG and 68Ga-DOTATATE PET imaging between January 2020 and September 2022 were enrolled. Dual tracer uptake patterns were classified into three groups: A. DOTATATE positive and FDG negative, B. DOTATATE positive and FDG positive, and C. DOTATATE negative and FDG positive. We evaluated the heterogeneity of patterns and staging changes. Morever, dual tracer uptake patterns and clinical factors were compared to progression-free survival (PFS) by cox regression.

Conference:

Presenting Author: Yi Z

Authors: Yi Z, Hui W, Ming Gang S, Rong T,

Keywords: 668Ga-DOTATATE, 18F-FDG, neuroendocrine tumor, prognosis,